Serum levels of osteoprotegerin and receptor activator of nuclear factor-κB ligand as markers of periprosthetic osteolysis

被引:38
|
作者
Granchi, Donatella
Pellacani, Andrea
Spina, Mauro
Cenni, Elisabetta
Savarino, Lucia Maria
Baldini, Nicola
Giunti, Armando
机构
[1] Ist Ortoped Rizzoli, Lab Pathophysiol Orthoped Implants, I-40136 Bologna, Italy
[2] Ist Ortoped Rizzoli, Orthoped & Traumatol Div 7, I-40136 Bologna, Italy
来源
关键词
D O I
10.2106/JBJS.E.01038
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Background: Previous studies have suggested that the balance between receptor activator of nuclear factor-kappa B ligand (RANKL) and its decoy-receptor osteoprotegerin (OPG) in local tissue seems to play a crucial role in the loosening of the total hip replacement. The aim of this study was to evaluate whether the circulating levels of OPG and RANKL, as well as their ratio, could be different in patients with aseptic loosening compared with patients with stable implants. Methods: One hundred and twenty-eight subjects were recruited. They included thirty-nine patients with osteoarthritis who had not yet undergone total hip arthroplasty, thirty-three patients who had undergone total hip arthroplasty and had clinically and radiographically stable implants, thirty-six patients with aseptic loosening of total hip arthroplasty components, and twenty healthy volunteers. Serum levels of OPG and RANKL were measured with use of an immunoenzymatic method, and in each individual the OPG-to-RANKL ratio was calculated. Results: In every group, a significant correlation was detected between OPG concentration and age (r = 0.58, p < 0.0001), especially in individuals older than fifty years, while gender and underlying disease were not found to influence serum levels of the tested parameters. In comparison with the levels in healthy donors and patients with a stable total hip replacement, the serum levels of OPG were increased in the patients who had not yet had an arthroplasty, those with aseptic loosening of a total hip replacement, and those with a cemented total hip replacement. Moreover, the OPG serum level provided good diagnostic accuracy in detecting the implant failure. A correlation was found between the sum of the osteolytic areas seen radiographically around the femoral stem and the RANKL level (r = 0.38, p = 0.02) and the OPG-to-RANKL ratio (r = -0.29, p = 0.04). Conclusions: An increase in OPG levels may reflect a protective mechanism of the skeleton to compensate for the osteolytic activity that occurs in severe osteoarthritis and in aseptic loosening. Prospective studies are needed to determine whether serum OPG levels could be used as markers for monitoring the stability of the implant, as well as for predicting aseptic loosening.
引用
收藏
页码:1501 / 1509
页数:9
相关论文
共 50 条
  • [1] Osteoprotegerin and receptor activator of nuclear factor-κB ligand (RANKL) in the serum of healthy adults
    Jung, K
    Lein, M
    Von Hösslin, K
    Grosse, A
    Roth, S
    Possinger, K
    Lüftner, D
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2002, 17 (03): : 177 - 181
  • [2] Plasma levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in patients with neuroblastoma
    Granchi, D
    Garaventa, A
    Amato, I
    Paolucci, P
    Baldini, N
    INTERNATIONAL JOURNAL OF CANCER, 2006, 119 (01) : 146 - 151
  • [3] The Role of Receptor Activator of Nuclear Factor-κB Ligand/Osteoprotegerin Ratio in Synovial Fluid as a Potential Marker for Periprosthetic Osteolysis Following Total Ankle Arthroplasty
    Lee, Gun-Woo
    Song, Ji-Eun
    Han, Jeong-Eun
    Kim, Nack-Sung
    Lee, Keun-Bae
    CLINICS IN ORTHOPEDIC SURGERY, 2024, 16 (04) : 661 - 668
  • [4] Gingival Crevicular Fluid Levels of Sclerostin, Osteoprotegerin, and Receptor Activator of Nuclear Factor-κB Ligand in Periodontitis
    Balli, Umut
    Aydogdu, Ahmet
    Dede, Figen Ongoz
    Turer, Cigdem Coskun
    Guven, Berrak
    JOURNAL OF PERIODONTOLOGY, 2015, 86 (12) : 1396 - 1404
  • [5] Acute changes in serum osteoprotegerin and receptor activator for nuclear factor-κB ligand levels in women with established osteoporosis treated with teriparatide
    Anastasilakis, Athanasios D.
    Goulis, Dimirtios G.
    Polyzos, Stergios A.
    Gerou, Spiridon
    Pavlidou, Vasiliki
    Koukoulis, George
    Avramidis, Avraam
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2008, 158 (03) : 411 - 415
  • [6] The Effect of Osteoprotegerin (OPG)/Receptor Activator of Nuclear Factor-κB Ligand (RANKL)/Receptor Activator of Nuclear Factor-κB (RANK) on Aortic Valve Calcified
    Luo, Wei
    Wang, Jing
    Yang, Xia
    Li, Junshan
    Song, Yanqiu
    Cong, Hongliang
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 2024, 54 (05): : 633 - 642
  • [7] Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
    Lorenz C. Hofbauer
    Armin E. Heufelder
    Journal of Molecular Medicine, 2001, 79 : 243 - 253
  • [8] Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-κB ligand and osteoprotegerin in plasma and serum
    Chan, BYY
    Buckley, KA
    Durham, BH
    Gallagher, JA
    Fraser, WD
    CLINICAL CHEMISTRY, 2003, 49 (12) : 2083 - 2085
  • [9] Role of receptor activator of nuclear factor-κB ligand and osteoprotegerin in bone cell biology
    Hofbauer, LC
    Heufelder, AE
    JOURNAL OF MOLECULAR MEDICINE-JMM, 2001, 79 (5-6): : 243 - 253
  • [10] Receptor activator of nuclear factor κB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis
    Grimaud, E
    Soubigou, L
    Couillaud, S
    Coipeau, P
    Moreau, A
    Passuti, N
    Gouin, F
    Redini, F
    Heymann, D
    AMERICAN JOURNAL OF PATHOLOGY, 2003, 163 (05): : 2021 - 2031